


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 3

## Complete If Known

Application Number	09/581,651
Filing Date	June 15, 2000
First Named Inventor	Schor et al.
Art Unit	1642
Examiner Name	Steven L. Rawlings
Attorney Docket Number	350013-72

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number - Kind Code <sup>2</sup> (if known)		
SR	1	US-4,980,279	12/25/90	PETERS et al.
	2	US-5,049,658	09/17/91	KIMIZUKA et al.
	3	US-5,124,155	06/23/92	REICH, Cary
	4	US-5,300,630	04/05/94	MATSUURA et al.
	5	US-5,571,679	11/05/96	SEKIGUCHI et al.
	6	US-5,629,291	05/13/97	RUOSLAHTI et al.

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)		
SR	7	EPO - 0 207 751	06/27/86	BARELLA, Francisco
	8	EPO - 0 344 134	05/25/89	ZARDI, Luciano
	9	PCT - WO 90/00567	01/25/90	SCHOR et al.
	10	PCT - WO 94/16085	07/21/94	IRANI, Meher
	11	PCT - WO 99/02674	01/21/99	SCHOR, Seth

Examiner Signature		Date Considered	11/15/04
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/581,6511
		Filing Date	June 15, 2000
		First Named Inventor	Schor et al.
		Group Art Unit	1642
		Examiner Name	Stephen L. Rawlings
		Attorney Docket Number	350013-72
Sheet 1 of 3			

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	2
	12	KORNBLIHTT, et al., Primary structure of h man fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO Sequence Database Accession No. X0271; 4:1755-1759(1985)	
	13	KORNBLIHTT et al., Primary structure of h man fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO, (USA) vol. 4 pp. 1755-1759 (1985)	
	14	KORNBLIHTT et al., SWISSPROT Sequence Database Accession No. P02751, (1986)	
	15	PIRI Sequence database (1985) Accession Ref. FNHU	
	16	DEAN et al., Cloning and analysis of the promoter region of the human fibronectin gene; Proc. Natl. Acad. Sci, USA, Vol. 84, pp. 1876-1880, April 1987	
	17	HYNES et al., EMBL Data library PIR2 AccessionNo. S14428, 1989	
	18	DESIMONE et al., Identification and characterization of alternatively spliced fibronectin mRNAs expressed in early Xenopus embryos, SWISSPROT Database Accession Ref. FINC_XENLA, Dev. Biol. vol. 149 pp. 357-369 (1992)	
	19	SCHOR, Fibroblast subpopulations as accelerators of tumor progression: The role of migration stimulating factor, Epithelial-Mesenchymal Interactions in Cancer, 1995 pp. 273-296, Switzerland	
	20	SCHOR et al., Migration stimulating factor (MSF): Its structure mode of action and possible function i health and disease; The Society of Experimental Biology 1993, pp. 235-251, UK	
	21	GREY et al., Purification of the migration stimulating factor produced by fetal and breast cancer patients fibroblasts, Proc. Natl. Acad. Sci, USA, Vol. 86, pp. 2438-2422, April 1989	
	22	SCHOR et al., Fetal-like fibroblasts: their production of migration stimulating factor and role in tumor progression, Mammary Tumorigenesis and Malignant Progression, pp. 277-298, 1994	
	23	IRWIN et al., Inter-and Intra-site heterogeneity in the expression of fetal-like phenotypic characteristic by gingival fibroblasts: potential significance for wound healing, Journal of Cell Science, Vol 107, p 1333-1346 (1994) UK	
	24	SCHOR et al., Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma, Int. J. Cancer, Vol. 59, pp. 25-32 (1994)	
	25	PICARDO et al., Migration stimulating activity in serum of breast cancer patients, The Lancet, Vol. 337, pp. 130-134, January 19, 1991	

12 11/15/04

Substitute for form 1449B/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	09/581,6511
		Filing Date	June 15, 2000
		First Named Inventor	Schor et al.
		Group Art Unit	1642
		Examiner Name	Stephen L. Rawlings
Sheet <u>1</u> of <u>3</u>	Attorney Docket Number	350013-72	



RECEIVED  
APR 01 2002  
TECH CENTER 1600/2900

SR	26	ELLIS et al., Antagonistic effects of TGF- $\beta$ 1 and MSF on fibroblast migration and hyaluronic acid synthesis, Possible implications for dermal wound healing, Journal of Cell Science, Vol. 102, pp. 447-45 (1992) UK
SR	27	PICARDO et al., Detection of migration stimulating activity in wound fluid, Experimental and Molecular Pathology Vol. 57, pp 8-21 (1992)
SR	28	SCHOR et al., Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implications for cancer pathogenesis, Cell Motility Factors, pp. 127-146, 1992
SR	29	SCHOR et al., Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics; Journal of Cell Science, Vol. 90, pp. 401-407 (1988) UK
SR	30	SCHOR et al., Fetal and cancer patient fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells, Journal of Cell Science, Vol. 90, pp. 391-399 (1988) UK
	31	SCHOR et al., Characterization of migration-stimulating factor (MSF): Evidence of its role in cancer pathogenesis, Cancer Investigation Vol. 8(6), pp. 665-667, (1990)
	32	SCHOR et al., Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: Effect on hyaluronic acid synthesis, In Vitro Cellular Development and Biology, Vol 25, Number 8, pp. 737-746, August 1989

Examiner Signature	<i>[Signature]</i>	Date Considered	11/15/04
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.